Indications and uses
Temporarily relieves itchy, red eyes due to: pollen ragweed grass animal hair and dander
Temporarily relieves itchy, red eyes due to: pollen ragweed grass animal hair and dander
adults and children 6 years of age and over: put 1 or 2 drops in the affected eye(s) up to four times a day children under 6 years of age: consult a doctor
Drug Facts
Naphazoline Hydrochloride 0.025%
Pheniramine Maleate 0.3%
Redness reliever
Antihistamine
Temporarily relieves itchy, red eyes due to:
For external use only
Do not use if you are sensitive to any ingredient in this product
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away. Accidental swallowing by infants and children may lead to coma and marked reduction in body temperature.
Boric Acid and Sodium Borate buffer system preserved with Benzalkonium Chloride (0.01%) and Edetate Disodium (0.1%), Sodium Hydroxide and/or Hydrochloric Acid (to adjust pH) and Water for injection.
1-800-932-5676
Principal Display Panel Text for Container Label:
NDC 68016-450-00
Premier
Value® Logo
Allergy
Eye Drops
ANTIHISTAMINE &
REDNESS RELIEVER
Naphazoline HCl 0.025% and
Pheniramine Maleate 0.3%
Ophthalmic Solution, USP
RELIEVES REDNESS
& ITCHY EYES
15 mL (0.5 FL OZ) STERILE

Principal Display Panel Text for Carton Label:
NDC 68016-450-00
*COMPARE TO THE
ACTIVE INGREDIENT
IN VISINE-A®
Premier
Value® Logo
Allergy
Eye Drops
ANTIHISTAMINE &
REDNESS RELIEVER
Naphazoline HCl 0.025% and
Pheniramine Maleate 0.3%
Ophthalmic Solution, USP
RELIEVES REDNESS &
ITCHY EYES DUE TO:
15 mL (0.5 FL OZ)
STERILE PV Brand Logo

| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68016-450-00 | 2020-10-21 | C162847 | 48780-1 | 9d75b9d0-4e88-f424-e053-dadaa90a57ce | 57e4f554-a0c5-46e1-8b19-dd6559b25c9f |
| 68016-450-00 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-4e88-f424-e053-dadaa90a57ce | 57e4f554-a0c5-46e1-8b19-dd6559b25c9f |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Naphazoline Hydrochloride | ACTIVE INGREDIENT | MZ1131787D | 3 | |
| Pheniramine Maleate | ACTIVE INGREDIENT | NYW905655B | 3 | |
| Naphazoline | ACTIVE MOIETY | H231GF11BV | 3 | |
| Pheniramine | ACTIVE MOIETY | 134FM9ZZ6M | 3 | |
| Benzalkonium Chloride | INACTIVE INGREDIENT | F5UM2KM3W7 | 3 | |
| Boric Acid | INACTIVE INGREDIENT | R57ZHV85D4 | 3 | |
| Edetate Disodium | INACTIVE INGREDIENT | 7FLD91C86K | 3 | |
| Hydrochloric Acid | INACTIVE INGREDIENT | QTT17582CB | 3 | |
| Sodium Borate | INACTIVE INGREDIENT | 91MBZ8H3QO | 3 | |
| Sodium Hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 3 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 3 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 68016-450 | 68016-450-00 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Naphazoline Hydrochloride | MZ1131787D | ACTIB |
| Pheniramine Maleate | NYW905655B | ACTIB |
| Boric Acid | R57ZHV85D4 | IACT |
| Sodium Borate | 91MBZ8H3QO | IACT |
| Benzalkonium Chloride | F5UM2KM3W7 | IACT |
| Edetate Disodium | 7FLD91C86K | IACT |
| Sodium Hydroxide | 55X04QC32I | IACT |
| Hydrochloric Acid | QTT17582CB | IACT |
| Water | 059QF0KO0R | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / RESPIRATORY (INHALATION) | 8 %w/v | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / EPIDURAL | ADJ PH | ||
| Benzalkonium Chloride | BENZALKONIUM CHLORIDE | F5UM2KM3W7 | INJECTION / INTRAMUSCULAR | 1 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAVENOUS | 2.78 %w/v | ||
| Boric Acid | BORIC ACID | R57ZHV85D4 | SUSPENSION/ DROPS / AURICULAR (OTIC) | 3 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRATUMOR | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | CONCENTRATE / ORAL | 2.17 mg/1ml | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / URETERAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPONGE / TOPICAL | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | ENEMA / RECTAL | 60 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | LIQUID / INTRAVENOUS | 0.03 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRATUMOR | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | DISC / TOPICAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / PARENTERAL | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | TABLET, DELAYED RELEASE / ORAL | 100 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / TOPICAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION/ DROPS / TOPICAL | ADJ PH | ||
| Sodium Borate | SODIUM BORATE | 91MBZ8H3QO | CREAM / TOPICAL | NA | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | GEL / TOPICAL | 10 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / EPIDURAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / EXTRACORPOREAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SUSPENSION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAVESICAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / ORAL | 223 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAOCULAR | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / OPHTHALMIC | 0.06 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / EPIDURAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 78.36 mg | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRABURSAL | 0.01 %w/v | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAOCULAR | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SOLUTION / INTRACARDIAC | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRATHECAL | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / DENTAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / OPHTHALMIC | 0.31 %w/v | ||
| Boric Acid | BORIC ACID | R57ZHV85D4 | INJECTION, SOLUTION / INTRAVENOUS | 210 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | ADJ PH | ||
| Boric Acid | BORIC ACID | R57ZHV85D4 | GEL / OPHTHALMIC | 0.5 %w/w | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRASPINAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, EMULSION / INTRAMUSCULAR | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRATHECAL | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / RESPIRATORY (INHALATION) | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | POWDER / INTRAVENOUS | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / INTRA-ARTICULAR | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION / INTRA-ARTICULAR | 0.05 %w/v | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, SOLUTION / INTRAMUSCULAR | 4 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION / INTRATUMOR | ADJ PH | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | LIQUID / ORAL | 4.46 mg/1ml | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SYRUP / ORAL | 2.03 mg/1ml | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | INJECTION, SUSPENSION, LIPOSOMAL / INTRAVENOUS | ADJ PH | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRADERMAL | ADJ PH | ||
| Edetate Disodium | EDETATE DISODIUM | 7FLD91C86K | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 19 mg | ||
| Hydrochloric Acid | HYDROCHLORIC ACID | QTT17582CB | SOLUTION / INTRAPERITONEAL | ADJ PH | ||
| Sodium Borate | SODIUM BORATE | 91MBZ8H3QO | SOLUTION / OPHTHALMIC | 2 mg | ||
| Sodium Hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / SUBARACHNOID | ADJ PH |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | A202795-001 | NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | 0.025%;0.3% | SOLUTION/DROPS / OPHTHALMIC | 2013-01-24 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 748afe52-0b29-4177-8a26-d12641f03efe | 57e4f554-a0c5-46e1-8b19-dd6559b25c9f | 2020-10-21 | Warnings | 57e4f554-a0c5-46e1-8b19-dd6559b25c9f |
Adverse event summaries are temporarily unavailable. Other product information remains available.